Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants With Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)

NCT07134088 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT07134088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07134088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants With Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)
Lead sponsor
Amgen
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 8, 2025
Completion date
September 16, 2032
Enrollment
104 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

minimal residual disease + b-cell acute lymphoblastic leukemia, relapsed/refractory b-cell precursor acute lymphoblastic leukemia